» Articles » PMID: 38172992

The Progression of Inorganic Nanoparticles and Natural Products for Inflammatory Bowel Disease

Overview
Publisher Biomed Central
Specialty Biotechnology
Date 2024 Jan 4
PMID 38172992
Authors
Affiliations
Soon will be listed here.
Abstract

There is a growing body of evidence indicating a close association between inflammatory bowel disease (IBD) and disrupted intestinal homeostasis. Excessive production of reactive oxygen species (ROS) and reactive nitrogen species (RNS), along with an increase in M1 proinflammatory macrophage infiltration during the activation of intestinal inflammation, plays a pivotal role in disrupting intestinal homeostasis in IBD. The overabundance of ROS/RNS can cause intestinal tissue damage and the disruption of crucial gut proteins, which ultimately compromises the integrity of the intestinal barrier. The proliferation of M1 macrophages contributes to an exaggerated immune response, further compromising the intestinal immune barrier. Currently, intestinal nanomaterials have gained widespread attention in the context of IBD due to their notable characteristics, including the ability to specifically target regions of interest, clear excess ROS/RNS, and mimic biological enzymes. In this review, we initially elucidated the gut microenvironment in IBD. Subsequently, we delineate therapeutic strategies involving two distinct types of nanomedicine, namely inorganic nanoparticles and natural product nanomaterials. Finally, we present a comprehensive overview of the promising prospects associated with the application of nanomedicine in future clinical settings for the treatment of IBD (graphic abstract). Different classes of nanomedicine are used to treat IBD. This review primarily elucidates the current etiology of inflammatory bowel disease and explores two prominent nanomaterial-based therapeutic approaches. First, it aims to eliminate excessive reactive oxygen species and reactive nitrogen species. Second, they focus on modulating the polarization of inflammatory macrophages and reducing the proportion of pro-inflammatory macrophages. Additionally, this article delves into the treatment of inflammatory bowel disease using inorganic metal nanomaterials and natural product nanomaterials.

Citing Articles

Probiotic nanocomposite materials with excellent resistance, inflammatory targeting, and multiple efficacies for enhanced treatment of colitis in mice.

Huang Y, Cai H, Liu H, Wang L, Feng G, Ding Z J Nanobiotechnology. 2025; 23(1):188.

PMID: 40055678 PMC: 11889847. DOI: 10.1186/s12951-025-03240-1.


Tumor-Associated Macrophages: Key Players in the Non-Small Cell Lung Cancer Tumor Microenvironment.

Lv T, Fan R, Wu J, Gong H, Gao X, Liu X Cancer Med. 2025; 14(3):e70670.

PMID: 39927632 PMC: 11808749. DOI: 10.1002/cam4.70670.


RNF128 deficiency in macrophages promotes colonic inflammation by suppressing the autophagic degradation of S100A8.

Ran X, Li Y, Ren Y, Chang W, Deng R, Wang H Cell Death Dis. 2025; 16(1):20.

PMID: 39809743 PMC: 11733159. DOI: 10.1038/s41419-025-07338-0.


Cell Membrane-Coated Nanotherapeutics for the Targeted Treatment of Acute and Chronic Colitis.

Li S, Chen L, Wu T, Wu J, Yang H, Ju Q Biomater Res. 2024; 28:0102.

PMID: 39512421 PMC: 11542430. DOI: 10.34133/bmr.0102.


Redox-manipulating nanocarriers for anticancer drug delivery: a systematic review.

Meng X, Shen Y, Zhao H, Lu X, Wang Z, Zhao Y J Nanobiotechnology. 2024; 22(1):587.

PMID: 39342211 PMC: 11438196. DOI: 10.1186/s12951-024-02859-w.


References
1.
Peer D, Karp J, Hong S, Farokhzad O, Margalit R, Langer R . Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2008; 2(12):751-60. DOI: 10.1038/nnano.2007.387. View

2.
Soh M, Kang D, Jeong H, Kim D, Kim D, Yang W . Ceria-Zirconia Nanoparticles as an Enhanced Multi-Antioxidant for Sepsis Treatment. Angew Chem Int Ed Engl. 2017; 56(38):11399-11403. DOI: 10.1002/anie.201704904. View

3.
Morita K, Furuse M, Fujimoto K, Tsukita S . Claudin multigene family encoding four-transmembrane domain protein components of tight junction strands. Proc Natl Acad Sci U S A. 1999; 96(2):511-6. PMC: 15167. DOI: 10.1073/pnas.96.2.511. View

4.
Caddeo C, Nacher A, Diez-Sales O, Merino-Sanjuan M, Fadda A, Manconi M . Chitosan-xanthan gum microparticle-based oral tablet for colon-targeted and sustained delivery of quercetin. J Microencapsul. 2014; 31(7):694-9. DOI: 10.3109/02652048.2014.913726. View

5.
Li T, Pan S, Gao S, Xiang W, Sun C, Cao W . Diselenide-Pemetrexed Assemblies for Combined Cancer Immuno-, Radio-, and Chemotherapies. Angew Chem Int Ed Engl. 2019; 59(7):2700-2704. DOI: 10.1002/anie.201914453. View